Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Controlled Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the AMA-1 Malaria Vaccine FMP2.1/AS02A Versus Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali

Next Previous
Trial Profile

Randomized, Controlled Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the AMA-1 Malaria Vaccine FMP2.1/AS02A Versus Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Malaria vaccine (Primary) ; AS02; Rabies vaccine
  • Indications Falciparum malaria
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline

Most Recent Events

  • 14 Oct 2011 Additional lead trial center identified as reported by ClinicalTrials.gov.
  • 15 Sep 2011 Primary endpoint 'Infection-rate' has not been met (3060803).
  • 15 Sep 2011 Results published in the New England Journal of Medicine.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top